{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:18Z","timestamp":1786119618317,"version":"build-2736575974"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Autoimmunity plays a major role in the pathogenesis of many neuromuscular disorders such as chronic inflammatory demyelinating polyneuropathy, Guillain-Barr\u00e9 syndrome, polymyositis, dermatomyositis, myasthenia gravis, Lambert Eaton syndrome, and stiff person syndrome. Although most of these disorders respond favorably to the commonly used immunomodulatory agents such as steroids, intravenous gamma globulin, plasmapheresis, and chemotherapy, some are initially refractory, whereas others gradually lose responsiveness. Therefore, alternative, selective, and novel immunosuppressive agents are used to treat these cases. Among these agents, rituximab has shown promise in some of the neuromuscular disorders with minimal side effects. Rituximab is a genetically engineered antibody that depletes CD20+ B-cells and is Food and Drug Administration- approved for treatment of non-Hodgkin lymphoma, CD20+ CLL, and rheumatoid arthritis. It carries a favorable side effects profile. However, evidence of efficacy is limited to case series and large prospective randomized controlled trials are lacking. In this article, we review and discuss the available literature on rituximab in treatment of various autoimmune neuromuscular diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cnd.0b013e3181ff49f3","type":"journal-article","created":{"date-parts":[[2010,11,15]],"date-time":"2010-11-15T23:49:42Z","timestamp":1289864982000},"page":"91-102","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["A Review: The Use of Rituximab in Neuromuscular Diseases"],"prefix":"10.1097","volume":"12","author":[{"given":"Homam","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen M","family":"Dimachkie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Shaibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20240808","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"R2-8-20240808","first-page":"84","article-title":"B-cells in multiple sclerosis.","volume":"13","author":"Duddy","year":"2006","journal-title":"Int MS J"},{"key":"R3-8-20240808","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab.","volume":"13","author":"Cerny","year":"2002","journal-title":"Anticancer Drugs"},{"key":"R4-8-20240808","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"R5-8-20240808","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"R6-8-20240808","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations.","volume":"328","year":"2004","journal-title":"BMJ"},{"key":"R7-8-20240808","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1378\/chest.129.1.174","article-title":"Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force.","volume":"129","author":"Guyatt","year":"2006","journal-title":"Chest"},{"key":"R8-8-20240808","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/brain\/124.1.145","article-title":"Intravenous immunoglobulin therapy in multifocal motor neuropathy. A double-blind, placebo-controlled study.","volume":"124","author":"Leger","year":"2001","journal-title":"Brain"},{"key":"R9-8-20240808","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/01.WNL.0000110185.23464.A1","article-title":"How long is IVIg effective in multifocal motor neuropathy?","volume":"62","author":"Terenghi","year":"2004","journal-title":"Neurology"},{"key":"R10-8-20240808","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.52.8.1701","article-title":"IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab.","volume":"52","author":"Levine","year":"1999","journal-title":"Neurology"},{"key":"R11-8-20240808","first-page":"485","article-title":"Treatment of IgM antibody associated polyneuropathies using rituximab, J Neurol Neurosurg Psychiatry.","volume":"74","author":"Pestronk","year":"2003","journal-title":""},{"key":"R12-8-20240808","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/mus.20664","article-title":"Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.","volume":"35","author":"Gorson","year":"2007","journal-title":"Muscle Nerve"},{"key":"R13-8-20240808","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.nmd.2009.04.013","article-title":"Effect of rituximab monotherapy in multifocal motor neuropathy.","volume":"19","author":"Stieglbauer","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"R14-8-20240808","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0079-6123(08)61957-3","article-title":"Antibodies to glycoconjugates in neuropathies and motor neuron disease.","volume":"101","author":"Latov","year":"1994","journal-title":"Prog Brain Res"},{"key":"R15-8-20240808","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/brain\/123.4.710","article-title":"Long-term prognosis of neuropathy associated with anti-MAG IgM proteins and its relationship to immune therapies.","volume":"123","author":"Nobile-Orazio","year":"2000","journal-title":"Brain"},{"key":"R16-8-20240808","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1212\/01.WNL.0000098996.02934.86","article-title":"Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab.","volume":"61","author":"Rojas-Garcia","year":"2003","journal-title":"Neurology"},{"key":"R17-8-20240808","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/mus.10359","article-title":"Rituximab in the treatment of polyneuropathy associated with anti MAG antibodies.","volume":"27","author":"Renaud","year":"2003","journal-title":"Muscle Nerve"},{"key":"R18-8-20240808","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1212\/01.wnl.0000201193.00382.b3","article-title":"High-dose rituximab and anti MAG associated polyneuropathy.","volume":"66","author":"Renaud","year":"2006","journal-title":"Neurology"},{"key":"R19-8-20240808","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1529-8027.2007.00129.x","article-title":"Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M.","volume":"12","author":"Benedetti","year":"2007","journal-title":"J Peripheral Nervous System"},{"key":"R20-8-20240808","first-page":"286","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy Ann Neurol.","volume":"65","author":"Dalakas","year":"2009","journal-title":""},{"key":"R21-8-20240808","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jneuroim.2006.10.014","article-title":"Pros and cons of treating murine myasthenia gravis with anti-C1q antibody.","volume":"182","author":"Tuzun","year":"2007","journal-title":"J Neuroimmunol"},{"key":"R22-8-20240808","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in seronegative myasthenia gravis.","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"R23-8-20240808","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s00277-005-1050-4","article-title":"Anti-CD20 antibody (rituximab) therapy in a myasthenia gravis patient with follicular lymphoma.","volume":"84","author":"Takagi","year":"2005","journal-title":"Ann Hematol"},{"key":"R24-8-20240808","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ajh.20169","article-title":"Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma.","volume":"77","author":"Gajra","year":"2004","journal-title":"Am J Hematol"},{"key":"R25-8-20240808","first-page":"237b","article-title":"Response of myasthenia gravis to rituximab in a patient with lymphoma: first report.","volume":"96","author":"Gajra","year":"2000","journal-title":"Blood"},{"key":"R26-8-20240808","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","article-title":"Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report.","volume":"143","author":"Wylam","year":"2003","journal-title":"J Pediatr"},{"key":"R27-8-20240808","first-page":"201","article-title":"Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients.","volume":"15","author":"Illa","year":"2008","journal-title":"J Neuroimmunol"},{"key":"R30-8-20240808","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant.","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"},{"key":"R31-8-20240808","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","article-title":"Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab.","volume":"33","author":"Hain","year":"2006","journal-title":"Muscle Nerve"},{"key":"R32-8-20240808","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-006-0442-2","article-title":"Rituximab in refractory MuSK antibody myasthenia gravis.","volume":"254","author":"Thakre","year":"2007","journal-title":"J Neurol"},{"key":"R33-8-20240808","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2008.02399.x","article-title":"Successful treatment of refractory generalized myasthenia gravis with rituximab.","volume":"16","author":"Lebrun","year":"2009","journal-title":"Eur J Neurol"},{"key":"R34-8-20240808","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CND.0b013e31819a8403","article-title":"Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review.","volume":"10","author":"Nelson","year":"2009","journal-title":"J Clin Neuromuscul Dis"},{"key":"R35-8-20240808","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study.","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R36-8-20240808","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1002\/art.22856","article-title":"Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients.","volume":"56","author":"Cooper","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R37-8-20240808","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","article-title":"A pilot trial of rituximab in the treatment of dermatomyositis.","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol"},{"key":"R38-8-20240808","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jns.2009.02.357","article-title":"Rituximab for myasthenia gravis: three case reports and review of the literature.","volume":"280","author":"Stieglbauer","year":"2009","journal-title":"J Neurol Sci"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00131402-201012000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:45:14Z","timestamp":1786041914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00131402-201012000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0b013e3181ff49f3","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}